# Kumar Prabhash

Source: https://onco.cc/people/prabhash-kumar/  
OnCo record `prabhash-kumar` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads medical oncology at Tata Memorial and its programme of pragmatic trials that make treatments affordable.

## Summary

Kumar Prabhash is Professor and Head of the Department of Medical Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai. He leads the department's programme of pragmatic trials that make treatments affordable, including trials of oral metronomic chemotherapy in head and neck cancer, low-cost EGFR tyrosine kinase inhibitor strategies in lung cancer and low-dose immunotherapy studies. His publications include a trial comparing gefitinib alone with gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. His interests are head and neck cancer, lung cancer, metronomic chemotherapy and pragmatic trials.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor and Head, Department of Medical Oncology, Tata Memorial Hospital
- Specialisms: Head and neck cancer; Lung cancer; Metronomic chemotherapy; Pragmatic trials

## Sources

- Tata Memorial Centre: https://tmc.gov.in
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Prabhash%20K%5BAuthor%5D%20Tata%20Memorial

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- institutions: [Advanced Centre for Treatment, Research and Education in Cancer](https://onco.cc/institutions/actrec/), [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- ideas: [Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live](https://onco.cc/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/)
- key papers: [Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)](https://onco.cc/key-papers/paper-patil-low-dose-nivolumab-jco-2023/), [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/)
- trials: [Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)](https://onco.cc/trials/gefitinib-chemo-tmh/), [Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)](https://onco.cc/trials/low-dose-nivolumab-tmh/), [Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)](https://onco.cc/trials/metronomic-vs-cisplatin-tmh/)

---
JSON: https://onco.cc/api/v1/entities/prabhash-kumar.json